HIGHLIGHTS
- who: Takashi Shigematsu and colleagues from the Department of Nephrology, Wakayama Medical University, Wakayama, Japan, Medical Affairs have published the paper: Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism, in the Journal: PLOS ONE of December/28,/2021
- what: This study evaluated the efficacy, including that on FGF23, and safety of evocalcet in the presence (low and high VDRA use) or absence of concomitant IV VDRA using a data set obtained from the previous phase 3 head-to-head comparison study in patients with SHPT who were on hemodialysis.
- how: The . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.